Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease

Journal of Neuroscience

Volumn 32, Issue 49, 2012, Pages 17921-17931

  Bagetta, Vincenza ^a   Sgobio, Carmelo ^a   Pendolino, Valentina ^a   Del Papa, Giulia ^a   Tozzi, Alessandro ^a,b   Ghiglieri, Veronica ^a   Giampà, Carmela ^a   Zianni, Elisa ^c   Gardoni, Fabrizio ^c   Calabresi, Paolo ^a,b   Picconi, Barbara ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; DOPAMINE 3 RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PRAMIPEXOLE; TUBULIN;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FRACTIONATION; CONTROLLED STUDY; DRUG MEGADOSE; DYSKINESIA; ELECTROPHYSIOLOGY; EXCITATORY POSTSYNAPTIC POTENTIAL; EXPERIMENTAL TEST; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PATCH CLAMP; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANIMALS; BENZOTHIAZOLES; CORPUS STRIATUM; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; EXCITATORY POSTSYNAPTIC POTENTIALS; LEVODOPA; MALE; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; RECEPTORS, AMPA; RECEPTORS, DOPAMINE D3; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84870542577     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2664-12.2012     Document Type: Article

References (60)

1. Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458. CrossRef Medline
2. Ahmed I, Bose SK, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G, Hammers A, Brooks DJ (2011) Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 134:979-986. CrossRef Medline
3. Bagetta V, Picconi B, Marinucci S, Sgobio C, Pendolino V, Ghiglieri V, Fusco FR, Giampà C, Calabresi P (2011) Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. J Neurosci 31:12513-12522. CrossRef Medline
4. Berthet A, Porras G, Doudnikoff E, Stark H, Cador M, Bezard E, Bloch B (2009) Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA induced dyskinesia. J Neurosci 29:4829-4835. CrossRef Medline
5. Birkmayer W, Hornykiewicz O (1998) The effect of l-3,4-dihydroxy phenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord 4:59-60. Medline
6. Blandini F, Armentero MT (2012) New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors. Expert Opin Investig Drugs 21: 153-168. CrossRef Medline
7. Bordet R, Ridray S, Schwartz JC, Sokoloff P (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12:2117-2123. CrossRef Medline
8. Calabresi P, Maj R, Pisani A, Mercuri NB, Bernardi G (1992) Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J Neurosci 12:4224-4233. Medline
9. Calabresi P, Mercuri NB, Sancesario G, Bernardi G (1993) Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116:433-452.
10. Calabresi P, Di Filippo M, Ghiglieri V, Picconi B (2008) Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 23 [Suppl 3]:S570-S579. Medline
11. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 9:1106-1117. CrossRef Medline
12. Calandrella D, Antonini A (2012) Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. Parkinsonism Relat Disord 18 [Suppl 1]:S120-S122. Medline
13. Cenci MA, Konradi C (2010) Maladaptive striatal plasticity in L-DOPA induced dyskinesia. Prog Brain Res 183:209-233. CrossRef Medline
14. Cenci MA, Lee CS, Björklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706. CrossRef Medline
15. 2+-permeable AMPA receptors: synaptic plasticity and beyond. Curr Opin Neurobiol 16:288-297. CrossRef Medline
16. Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA induced dyskinesia and histone activation. Biol Psychiatry 66:603-613. Medline
17. Dunah AW, Standaert DG (2003) Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum. J Neurochem 85:935-943. CrossRef Medline
18. Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG (2004) Dopamine D1-dependent trafficking of striatal N-methyl- D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol 65:121-129. CrossRef Medline
19. Feyder M, Bonito-Oliva A, Fisone G (2011) L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci 5:71. Medline
20. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C (2008) Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74:59-69. CrossRef Medline
21. Fisone G, Bezard E (2011) Molecular mechanisms of l-DOPA-induced dyskinesia. Int Rev Neurobiol 98:95-122. Medline
22. Gardoni F, Di LucaM (2006) New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 545:2-10. Medline
23. Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G, Cattabeni F, Di Luca M, Calabresi P (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci 26:2914-2922. CrossRef Medline
24. Gardoni F, Sgobio C, Pendolino V, Calabresi P, Di Luca M, Picconi B (2012) Targeting NR2A-containingNMDAreceptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging 33:2138-2144. Medline
25. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P (2003) Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110:1119-1127. CrossRef Medline
26. Gottwald MD, Aminoff MJ (2011) Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol 69:919-927. CrossRef Medline
27. Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E (2007) Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic nonhuman primates. Neurobiol Dis 26:452-463. Medline
28. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE (2007) Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22:2409-2417. CrossRef Medline
29. Hayashi T, Huganir RL (2004) Tyrosine phosphorylation and regulation of the AMPA receptor by SRC family tyrosine kinases. J Neurosci 24:6152-6160. CrossRef Medline
30. Isaac JT, Ashby MC, McBain CJ (2007) The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron 54:859-871. CrossRef Medline
31. Jenkinson C, Dummett S, Kelly L, Peters M, Dawson J, Morley D, Fitzpatrick R (2012) The development and validation of a quality of life measure for the carers of people with Parkinson's disease (the PDQ-Carer). Parkinsonism Relat Disorders 18:483-487. CrossRef Medline
32. Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9:665-677. Medline
33. Jenner P, McCreary AC, Scheller DK (2011) Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm 118:1691-1702. CrossRef Medline
34. Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P (2010) Calciumpermeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. J Neurochem 114: 499-511. CrossRef Medline
35. Lebel M, Chagniel L, Bureau G, Cyr M (2010) Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis 38:59-67. Medline
36. Lees AJ, Hardy J, Revesz T (2009) Parkinson's disease. Lancet 373:2055-2066. CrossRef Medline
37. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132. CrossRef Medline
38. Marcellino D, Ferré S, Casadó V, Cortés A, Le Foll B, Mazzola C, Drago F, Saur O, Stark H, Soriano A, Barnes C, Goldberg SR, Lluis C, Fuxe K, Franco R (2008) Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283:26016-26025. CrossRef Medline
39. 2+ permeability of AMPA-selective glutamate receptor channels. Biochem Biophys Res Commun 180:813-821. Medline
40. Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23:S2-S7. CrossRef Medline
41. Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5:677-687. CrossRef Medline
42. Ozawa S, Kamiya H, Tsuzuki K (1998) Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 54:581-618. Medline
43. Paillé V, Henry V, Lescaudron L, Brachet P, Damier P (2007) Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov Disord 22:533-539. CrossRef Medline
44. Paillé V, Picconi B, Bagetta V, Ghiglieri V, Sgobio C, di Filippo M, Viscomi MT, Giampà C, Fusco FR, Gardoni F, Bernardi G, Greengard P, di Luca M, Calabresi P (2010) Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 30:14182-14193. CrossRef Medline
45. Pellegrini-Giampietro DE, Gorter JA, Bennett MV, Zukin RS (1997) The GluR2 (GluR-B) hypothesis: Ca(2+)-permeable AMPA receptors in neurological disorders. Trends Neurosci 20:464-470. CrossRef Medline
46. Picconi B, Centonze D, Håkansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501-506. Medline
47. Picconi B, Centonze D, Rossi S, Bernardi G, Calabresi P (2004) Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain 127:1661-1669. CrossRef Medline
48. Picconi B, Bagetta V, Ghiglieri V, Paillè V, di Filippo M, Pendolino V, Tozzi A, Giampà C, Fusco FR, Sgobio C, Calabresi P (2011) Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 134:375-387. CrossRef Medline
49. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484-1491. CrossRef Medline
50. Rascol O, Lozano A, Stern M, Poewe W (2011) Milestones in Parkinson's disease therapeutics. Mov Disord 26:1072-1082. CrossRef Medline
51. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55 [Suppl 1]:23-30. Medline
52. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, Hervé D, Greengard P, Fisone G (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27:6995-7005. CrossRef Medline
53. Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275-331. Medline
54. Tang K, Low MJ, Grandy DK, Lovinger DM (2001) Dopamine-dependent synaptic plasticity in striatum during in vivo development. Proc Natl Acad Sci U S A 98:1255-1260. CrossRef Medline
55. VanLeeuwen JE, Petzinger GM, Walsh JP, Akopian GK, Vuckovic M, Jakowec MW (2010) Altered AMPA receptor expression with treadmill exercise in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci Res 88:650-668. Medline
56. Varanese S, Howard J, di Rocco A (2010) NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease. Mov Disord 25:508-510. CrossRef Medline
57. Vastagh C, Gardoni F, Bagetta V, Stanic J, Zianni E, Giampà C, Picconi B, Calabresi P, Di LucaM (2012) NMDA receptor composition modulates dendritic spine morphology in striatal medium spiny neurons. J Biol Chem 287:18103-18114. CrossRef Medline
58. Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM (2009) Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiol Dis 35:184-192. Medline
59. Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E (2009) Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 8:1140-1149. CrossRef Medline
60. Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL, Earl NL (2010) Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 25:858-866. CrossRef Medline